Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Takeda Pharmaceutical Company Limited (4502.T)

Tokyo - Tokyo Delayed Price. Currency in JPY
Add to watchlist
3,801.000.00 (0.00%)
At close: 03:15PM JST
Advertisement

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo 103-8668
Japan
81 3 3278 2111
https://www.takeda.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees47,347

Key Executives

NameTitlePayExercisedYear Born
Mr. Christophe WeberPres, CEO & Representative Director594MN/A1966
Mr. Constantine SaroukosCFO & Representative Director355MN/A1971
Dr. Andrew S. PlumpPres of R&D and Representative Director337MN/A1965
Dr. Seigo IzumoChair of Management BoardN/AN/AN/A
Mr. Haruhiko HirateMember of Management BoardN/AN/A1957
Salvatore AlesciMember of Management Board and Head of R&D Global Science & Biomedical PolicyN/AN/AN/A
Norimasa TakedaChief Accounting Officer & Corp. ControllerN/AN/AN/A
Mr. Iwaaki TaniguchiSr. VP of Corp. Fin. & Controlling DepartmentN/AN/AN/A
Mr. Gabriele RicciChief Data & Technology OfficerN/AN/A1978
Mr. Christopher David O'ReillyGlobal Head of Investor Relations & Global Fin.N/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

Corporate Governance

Takeda Pharmaceutical Company Limited’s ISS Governance QualityScore as of July 31, 2022 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement